To The Moon

This morning, Innovent Biologics surged sharply, at one point rising over 12% to hit a record high of HK$112.6, with its market capitalization exceeding HK$190 billion, making it the second pharmaceutical stock this year, after WuXi AppTec, to reach an all-time high.

On the news front, Innovent Biologics released its earnings report on August 25. The company posted first-half revenue of RMB 8.6 billion, up 45% year-on-year, slightly missing Bloomberg consensus estimates by 1.1%. The company’s adjusted comparable net profit reached RMB 1.25 billion, exceeding the Bloomberg consensus of RMB 896 million and already surpassing the full-year level of the previous year. In addition, the company clearly set a 2030 revenue target of RMB 35–40 billion.

Over the past ten months, Innovent Biologics has entered into intensive strategic partnerships with multinational pharmaceutical companies including Takeda, Eli Lilly, and Pfizer, with aggregate transaction value reaching US$34 billion, accounting for over 30% of China’s total out-licensing deal value during the same period. Among these, five core assets adopted high-level collaboration models involving global co-development, co-commercialization, and revenue sharing, rather than simple single-asset rights sales, signaling strong development momentum.

On institutional views, Nomura analysts noted that driven by improvements in drug gross margins, lower operating expenses, and reductions in other costs, the company’s net profit grew 50% year-on-year to RMB 1.3 billion, exceeding both the firm’s and Bloomberg consensus estimates. The robust growth in product sales was attributed to a rich portfolio of drug pipelines and accelerated volume growth of oncology drugs included in the National Reimbursement Drug List (NRDL).

Additionally, JPMorgan increased its stake in Innovent Biologics by 2.3554 million shares, raising its shareholding ratio to 5.06%, reflecting confidence in the company.

So far this year, out-licensing deals by Chinese pharmaceutical companies have surpassed US$100 billion in aggregate value. The innovative drug sector has now entered a phase of earnings delivery. Coupled with breakthroughs in mRNA medicines and a series of upcoming academic conferences such as the World Conference on Lung Cancer in September and October, the industry is poised to enter a new round of intensive data catalysts.$信达生物(01801)$

Don’t miss out on the innovative drug rally – ETFs can help you build your asset allocation.

$华夏恒生生科(03069)$ tracks the Hang Seng Hong Kong‑listed Biotech Index, covering 50 Hong Kong‑listed biotech companies. The fund size is approximately HK$2.668 billion. Its holding in Innovent Biologics is about 10.03%, with major positions also in BeiGene, WuXi Biologics, WuXi AppTec, and others.

$GX中国生科(02820)$ tracks the Solactive China Biotech Index, with a fund size of about HK$0.7 billion (and approximately HK$0.77 billion as noted). Innovent Biologics accounts for roughly 12.45% of its portfolio. It covers over 30 companies listed in Hong Kong, A‑shares, and the U.S., with other top holdings including WuXi AppTec, BeiGene, WuXi Biologics, and A‑share listed Hengrui Medicine, among others.

$南方恒生生科(03174)$ tracks the Hang Seng Biotech Index constituents, with a fund size of about HK$0.989 billion. Its position in Innovent Biologics is around 10.36%, and it also has significant holdings in BeiGene, WuXi Biologics, WuXi Biologics (duplicated in source), Akeso, and others.